Grazoprevir
Clinical data | |
---|---|
Trade names | Zepatier (combination with elbasvir) |
Other names | MK-5172 |
License data | |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 98.8% |
Metabolism | CYP3A4 |
Elimination half-life | 31 hours |
Excretion | >90% via faeces, <1% via urine |
Identifiers | |
| |
JSmol ) | |
| |
|
Grazoprevir is a drug
Grazoprevir is a second generation
4A protease targets.[3] It has good activity against a range of HCV genotype variants, including some that are resistant to most currently used antiviral medications.[4][5]
Side effects
Side effects have only been assessed in the combination with
reduced appetite, and headache. Low red blood cell count has occurred when co-administered with ribavirin in some cases.[6][7] The most important risks are alanine transaminase elevation, hyperbilirubinemia, drug resistance development and drug interactions.[8]
Interactions
Grazoprevir is transported by the
SLCO1B3. Drugs that inhibit this proteins, such as rifampicin, ciclosporin, and a number of AIDS medications (atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cobicistat
), can cause a significant increase in grazoprevir blood plasma levels.
The substance is degraded by the liver enzyme St. John's wort, can lead to ineffectively low plasma levels of grazoprevir. Combination with CYP3A4 inhibitors may increase plasma levels.[7][9]
Pharmacology
Mechanism of action
Grazoprevir blocks
Pharmacokinetics
Grazoprevir reaches peak plasma concentrations two hours after oral intake together with elbasvir (variation between patients: 30 minutes to three hours). In hepatitis C patients, steady state concentrations are found after about six days.
faeces, and less than 1% via the urine.[7]
References
- ^ "FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4". Food and Drug Administration. 2018-11-03.
- PMID 25467591.
- PMID 24900473.
- PMID 22615282.
- S2CID 207477059.
- ^ "ZEPATIER (elbasvir and grazoprevir) Tablets, for Oral Use. Full Prescribing Information" (PDF). Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Retrieved 31 January 2016.
- ^ a b c d Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
- ^ "European Public Assessment Report" (PDF). European Medicines Agency. Retrieved 16 December 2017.
- ^ FDA Professional Drug Information on Zepatier.